Literature DB >> 19996758

Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent.

Patricia A Perone1, Stephanie L Weber, Marissa DaSilva, Tejaswi Paruchuri, Narasimharao Bhagavathula, Muhammad N Aslam, Michael K Dame, Kent J Johnson, Richard D Swartz, James Varani.   

Abstract

OBJECTIVE: Human skin produces increased amounts of matrix metalloproteinase-1 (MMP-1) when exposed in organ culture to Omniscan, one of the gadolinium-based MRI contrast agents (GBCA). MMP-1, by virtue of its ability to degrade structural collagen, contributes to collagen turnover in the skin. The objective of the present study was to determine whether collagenolytic activity was concomitantly up-regulated with increased enzyme.
MATERIALS AND METHODS: Skin biopsies from normal volunteers were exposed in organ culture to Omniscan. Organ culture fluids obtained from control and treated skin were examined for ability to degrade type I collagen. The same culture fluids were examined for levels of MMP-1, tissue inhibitor of metalloproteinases-1 (TIMP-1), and complexes of MMP-1 and TIMP-1.
RESULTS: Although MMP-1 was increased in culture fluid from Omniscan-treated skin, there was no increase in collagenolytic activity. In fact, collagenolytic activity declined. Increased production of TIMP-1 was also observed in Omniscan-treated skin, and the absolute amount of TIMP-1 was greater than the amount of MMP-1. Virtually all of the MMP-1 was present in MMP-1-TIMP-1 complexes, but the majority of TIMP-1 was not associated with MMP-1. When human dermal fibroblasts were exposed to TIMP-1 (up to 250 ng/mL), no increase in proliferation was observed, but an increase in collagen deposition into the cell layer was seen.
CONCLUSION: Gadolinium-based MRI contrast agent exposure has recently been linked to a fibrotic skin condition in patients with impaired kidney function. The mechanism is unknown. The increase in TIMP-1 production and concomitant reduction in collagenolytic activity demonstrated here could result in decreased collagen turnover and increased deposition of collagen in lesional skin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19996758      PMCID: PMC2819152          DOI: 10.1097/RLI.0b013e3181bf95eb

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  54 in total

1.  Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts.

Authors:  A Barchowsky; D Frleta; M P Vincenti
Journal:  Cytokine       Date:  2000-10       Impact factor: 3.861

2.  Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model.

Authors:  H Yoshiji; S Kuriyama; Y Miyamoto; U P Thorgeirsson; D E Gomez; M Kawata; J Yoshii; Y Ikenaka; R Noguchi; H Tsujinoue; T Nakatani; S S Thorgeirsson; H Fukui
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

Review 3.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.

Authors:  Robert Visse; Hideaki Nagase
Journal:  Circ Res       Date:  2003-05-02       Impact factor: 17.367

Review 4.  Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis.

Authors:  Anne Marie McNeill; Ronald J Barr
Journal:  Int J Dermatol       Date:  2002-06       Impact factor: 2.736

5.  Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.

Authors:  Julie King; Jing Zhao; Phillip Clingan; David Morris
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

6.  Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay.

Authors:  Hisanobu Mizumoto; Tsuyoshi Saito; Koji Ashihara; Makoto Nishimura; Masaki Takehara; Ryoichi Tanaka; Eiki Ito; Ryuichi Kudo
Journal:  Life Sci       Date:  2002-06-07       Impact factor: 5.037

7.  Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse.

Authors:  Hitoshi Yoshiji; Shigeki Kuriyama; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Toshiya Nakatani; Hirohisa Tsujinoue; Koji Yanase; Tadashi Namisaki; Hiroo Imazu; Hiroshi Fukui
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

8.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

9.  Inhibition of type I procollagen production in photodamage: correlation between presence of high molecular weight collagen fragments and reduced procollagen synthesis.

Authors:  James Varani; Patricia Perone; Suzanne E G Fligiel; Gary J Fisher; John J Voorhees
Journal:  J Invest Dermatol       Date:  2002-07       Impact factor: 8.551

Review 10.  Inflammation in end-stage renal failure: could it be treated?

Authors:  Peter Stenvinkel
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

View more
  7 in total

1.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

2.  Stimulation of fibroblast proliferation by insoluble gadolinium salts.

Authors:  Katherine Bleavins; Patricia Perone; Madhav Naik; Muneeb Rehman; Muhammad N Aslam; Michael K Dame; Sasha Meshinchi; Narasimharao Bhagavathula; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-09-01       Impact factor: 3.738

3.  Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents.

Authors:  P J Wermuth; S A Jimenez
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

4.  Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury.

Authors:  William Jenkins; Patricia Perone; Kyle Walker; Narasimharao Bhagavathula; Muhammad Nadeem Aslam; Marissa DaSilva; Michael K Dame; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-04-12       Impact factor: 3.738

5.  Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer.

Authors:  Bruce L Riser; Jeffrey L Barnes; James Varani
Journal:  J Cell Commun Signal       Date:  2015-12-23       Impact factor: 5.782

6.  Fibroblast response to gadolinium: role for platelet-derived growth factor receptor.

Authors:  Narasimharao Bhagavathula; Michael K Dame; Marissa DaSilva; William Jenkins; Muhammad N Aslam; Patricia Perone; James Varani
Journal:  Invest Radiol       Date:  2010-12       Impact factor: 6.016

7.  Understanding nephrogenic systemic fibrosis.

Authors:  Tushar Chopra; Kiran Kandukurti; Silvi Shah; Raheel Ahmed; Mandip Panesar
Journal:  Int J Nephrol       Date:  2012-11-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.